DSS Inc. Issues Letter to Shareholders
2023年10月12日 - 9:25PM
DSS, Inc. (NYSE American: DSS), a multinational company operating
nine (9) diversified business lines developed through strategic
acquisitions to build shareholder value through periodic spinoffs
to its shareholders, announced today that it has issued a Letter to
Shareholders.
Dear Valued Shareholders,
On behalf of the management team at DSS, Inc., I am pleased to
provide an update on our progress so far this year and our
expectations going into the end of the year.
While 2023 has been punctuated by global challenges, our
collective perseverance and adaptability have been paramount. I
remain proud of our resiliency and achievements, and I am looking
forward to significant growth remainder of this yea and the coming
year. We continue to embrace a diversified portfolio and seek out
investment opportunities through our extensive channels and
strategic partnerships, while also identifying ways to maximize
shareholder value.
I would like to highlight three specific developments.
As previously announced, we are in the late stages of preparing
for an Initial Public Offering (IPO) of our majority owned
subsidiary, Impact Biomedical, Inc. (IBIO), after distributing four
shares of IBIO for every share of DSS held as of the record date of
July 10, 2023.
Once the IPO has been completed, these stock dividend shares
will not be eligible for resale until 180 days from the effective
date of the IPO, a restriction that can be lifted at the discretion
of IBIO. The structure of this spinoff is designed for DSS to
maintain the consolidation of IBIO's financials, ensuring our
shareholders receive the benefits of IBIO’s success on a go forward
basis. Our license agreement with ProPhase Labs
(Nasdaq:PRPH) is resulting in promising clinical advancement
in the development of our Linebacker and Equivir assets.
Turning to our product packaging division, Premier Packaging
Corporation, Inc., I am elated to report significant growth.
Revenue for the first half of 2023 surged to $9.66 million, a 27%
increase over the same period in 2022. This growth is a testament
to the success of our capital investment in Premier, which has
catalyzed operational efficiencies and enriched profit margins.
Our commitment to reinforcing our leadership dynamics is evident
in the recent enhancement of the management team at DSS Wealth
Management, Inc. This deliberate move is aimed at fostering a
legacy of investment excellence and scaling our assets under
management. As the advisor to DSS AmericaFirst Funds, DSS Wealth
added Daniel Lew, CFA, as Chief Investment Officer and Portfolio
Manager, Jim Monaghan, CMT, as Chief Operating Officer and Chief
Compliance Officer and Michael Cheah, CFA, as Portfolio Manager
& Head of Fixed Income. The team collectively has over 100
years of investment industry experience and has worked closely
together for almost a decade. We are planning to launch a Total
Return Bond Fund, managed by Michael Cheah, to capitalize on the
prevailing higher interest rates.
Post the Impact Biomedical IPO, we eagerly look forward to
introducing our shareholders to our subsequent spinoffs or similar
liquidity events. A strategic facet of our approach remains the
monetization of our minority interest–be it through mergers or
acquisitions.
In closing, the trust and support of our shareholders have been
instrumental in shaping our journey. I extend heartfelt gratitude
for your unwavering belief in DSS, Inc. Here's to the promising
road ahead.
Regards,
Frank Heuszel
CEODSS, Inc.
About DSS, Inc.,
DSS is a multinational company operating businesses within
nine(9) divisions: Product Packaging, Biotechnology, Commercial
Lending, Securities and Investment Management, Alternative Trading,
Digital Transformation, Secure Living, and Alternative Energy. DSS
strategically acquires and develops assets to increase shareholder
value through periodic IPO spinoffs. Since 2019, under the guidance
of new leadership, DSS has built the necessary foundation for
achievable growth through the formation of a diversified portfolio
of companies positioned to drive profitability in multiple
high-growth sectors.
For more information on DSS visit https://www.dssworld.com
Safe Harbor Disclosure
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements include, but are not limited to,
statements related to the Company's intended use of proceeds and
other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are
subject to risks and uncertainties that may cause actual results or
events to differ materially from those projected. These risks and
uncertainties, many of which are beyond our control, include: risks
relating to our growth strategy; our ability to obtain, perform
under and maintain financing and strategic agreements and
relationships; risks relating to the results of development
activities; our ability to attract, integrate and retain key
personnel; our need for substantial additional funds; patent and
intellectual property matters; competition; as well as other risks
described in our SEC filings, including, without limitation, our
reports on Forms 8-K, 10-K and 10-Q, all of which can be obtained
on the SEC website at www.sec.gov. Readers are cautioned not to
place undue reliance on the forward-looking statements, which speak
only as of the date on which they are made and reflect management's
current estimates, projections, expectations, and beliefs. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions, or circumstances on which any such
statement is based, except as required by law.
Contact:DSS Inc. Investor RelationsIR@dssworld.com+1 (585)
565-2422
ProPhase Labs (NASDAQ:PRPH)
過去 株価チャート
から 12 2024 まで 1 2025
ProPhase Labs (NASDAQ:PRPH)
過去 株価チャート
から 1 2024 まで 1 2025